DUOFAG® and its journey to conquest diabetic foot infections

a 2022

DUOFAG® and its journey to conquest diabetic foot infections

ŠTVERÁKOVÁ, Dana, Martin BENEŠÍK, Tibor BOTKA, Dominik DOSTÁL, Andrea BUCHTOVÁ et. al.

Základní údaje

Originální název

DUOFAG® and its journey to conquest diabetic foot infections

Autoři

ŠTVERÁKOVÁ, Dana (203 Česká republika), Martin BENEŠÍK (203 Česká republika, domácí), Tibor BOTKA (203 Česká republika, domácí), Dominik DOSTÁL (203 Česká republika), Andrea BUCHTOVÁ, Milan BUŇATA a Marek MOŠA

Vydání

Viruses of Microbes 2022, Guimarães, Portugal, 2022, 2022

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

10600 1.6 Biological sciences

Stát vydavatele

Portugalsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Viruses of Microbes 2022

Kód RIV

RIV/00216224:14310/22:00129691

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova anglicky

phage therapy; diabetic foot; phage cocktail; Staphylococcus aureus; Pseudomonas aeruginosa

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 4. 11. 2022 15:07, Mgr. Tibor Botka, Ph.D.

Anotace

V originále

In Czechia, the history of phage therapy research dates back to interwar Czechoslovakia, but currently, phage therapy is almost unavailable there. Over the last decade, MB PHARMA has been working on phage research and has developed the phage cocktail DUOFAG®. This cocktail comprises phages active against Staphylococcus aureus and Pseudomonas aeruginosa. DUOFAG® is intended for diabetic foot infections treatment but has the potential for curing other types of infections too. DUOFAG® comprises two phages active against S. aureus and one phage active against P. aeruginosa. The phages characterized on morphological and genomic levels have their host ranges examined on hundreds of clinical isolates of bacteria. DUOFAG® is manufactured in a Czech GMP-certified facility. Elaborate release testing discussed with the State Institute for Drug Control ensures the quality of DUOFAG®. The stability of phages is evaluated regularly. MB PHARMA has established a seed lot system for phages and propagation bacteria. DUOFAG® was examined in preclinical animal studies. Acute dermal toxicity study on rats and local dermal tolerance study on rabbits confirmed the safety of DUOFAG®. Follow-up preclinical studies focusing on subcutaneous administration of DUOFAG® are currently underway. Single and repeated dose toxicity and toxicokinetics studies of DUOFAG® are performed on rats. According to data from Czech hospitals, S. aureus and P. aeruginosa are the main causative agents of diabetic foot infections. The upcoming clinical evaluation of DUOFAG® focuses on proving the safety, tolerability, and efficiency of multiple doses of DUOFAG® in subjects with infected diabetic foot ulcers. The first cohort of patients will be observed for safety evaluation of DUOFAG®, and possible adverse effects will be monitored. In Cohort 2, the study will continue as a double-blind, randomized add-on study of DUOFAG® vs. placebo. The wound healing rate and the microbiological load will be evaluated.

Návaznosti

NU21J-05-00035, projekt VaV

Název: Synergie lytických bakteriofágů a antibiotik v léčbě povrchových infekcí způsobených Staphylococcus aureus (Akronym: PAS-based therapy of S. aureus infections)

Investor: Ministerstvo zdravotnictví ČR, Synergy of lytic bacteriophages and antibiotics in the therapy of topical infections of Staphylococcus aureus, Podprogram 2 - juniorský - výzkumníci do 35 let

Citovat

ŠTVERÁKOVÁ, Dana, Martin BENEŠÍK, Tibor BOTKA, Dominik DOSTÁL, Andrea BUCHTOVÁ, Milan BUŇATA a Marek MOŠA. DUOFAG® and its journey to conquest diabetic foot infections. In Viruses of Microbes 2022, Guimarães, Portugal, 2022. 2022.

@proceedings{2225518,
   author = {Štveráková, Dana and Benešík, Martin and Botka, Tibor and Dostál, Dominik and Buchtová, Andrea and Buňata, Milan and Moša, Marek},
   booktitle = {Viruses of Microbes 2022, Guimarães, Portugal, 2022},
   keywords = {phage therapy; diabetic foot; phage cocktail; Staphylococcus aureus; Pseudomonas aeruginosa},
   language = {eng},
   title = {DUOFAG® and its journey to conquest diabetic foot infections},
   url = {https://skyros-congressos.pt/vom2022/},
   year = {2022}
}

TY  - CONF
ID  - 2225518
AU  - Štveráková, Dana - Benešík, Martin - Botka, Tibor - Dostál, Dominik - Buchtová, Andrea - Buňata, Milan - Moša, Marek
PY  - 2022
TI  - DUOFAG® and its journey to conquest diabetic foot infections
KW  - phage therapy
KW  - diabetic foot
KW  - phage cocktail
KW  - Staphylococcus aureus
KW  - Pseudomonas aeruginosa
UR  - https://skyros-congressos.pt/vom2022/
N2  - In Czechia, the history of phage therapy research dates back to interwar Czechoslovakia, but currently, phage therapy is almost unavailable there. Over the last decade, MB PHARMA has been working on phage research and has developed the phage cocktail DUOFAG®. This cocktail comprises phages active against Staphylococcus aureus and Pseudomonas aeruginosa. DUOFAG® is intended for diabetic foot infections treatment but has the potential for curing other types of infections too. DUOFAG® comprises two phages active against S. aureus and one phage active against P. aeruginosa. The phages characterized on morphological and genomic levels have their host ranges examined on hundreds of clinical isolates of bacteria. DUOFAG® is manufactured in a Czech GMP-certified facility. Elaborate release testing discussed with the State Institute for Drug Control ensures the quality of DUOFAG®. The stability of phages is evaluated regularly. MB PHARMA has established a seed lot system for phages and propagation bacteria. DUOFAG® was examined in preclinical animal studies. Acute dermal toxicity study on rats and local dermal tolerance study on rabbits confirmed the safety of DUOFAG®. Follow-up preclinical studies focusing on subcutaneous administration of DUOFAG® are currently underway. Single and repeated dose toxicity and toxicokinetics studies of DUOFAG® are performed on rats. According to data from Czech hospitals, S. aureus and P. aeruginosa are the main causative agents of diabetic foot infections. The upcoming clinical evaluation of DUOFAG® focuses on proving the safety, tolerability, and efficiency of multiple doses of DUOFAG® in subjects with infected diabetic foot ulcers. The first cohort of patients will be observed for safety evaluation of DUOFAG®, and possible adverse effects will be monitored. In Cohort 2, the study will continue as a double-blind, randomized add-on study of DUOFAG® vs. placebo. The wound healing rate and the microbiological load will be evaluated.
ER  -

ŠTVERÁKOVÁ, Dana, Martin BENEŠÍK, Tibor BOTKA, Dominik DOSTÁL, Andrea BUCHTOVÁ, Milan BUŇATA a Marek MOŠA. DUOFAG® and its journey to conquest diabetic foot infections. In \textit{Viruses of Microbes 2022, Guimarães, Portugal, 2022}. 2022.

Podrobný výpis o publikaci